Biophytis S.A.
Clinical-stage biotech developing therapeutics for age-related degenerative diseases.
ALBPS | PA
Overview
Corporate Details
- ISIN(s):
- FR0012816825 (+4 more)
- LEI:
- 9695008GIE061NBGU106
- Country:
- France
- Address:
- 14 AVENUE DE L'OPERA, 75001 PARIS
- Website:
- https://www.biophytis.com/en/
Description
Biophytis S.A. is a clinical-stage biotechnology company focused on developing therapeutics to slow degenerative processes associated with aging and improve longevity. The company's primary strategy is centered on treating diseases that impair mobility. Its lead drug candidate, BIO101, is being advanced in late-stage clinical development for multiple age-related conditions. A key program is the SARA Phase 3 trial, the first-ever pivotal study for the treatment of sarcopenia (age-related muscle loss). Additionally, BIO101 is being evaluated in the OBA Phase 2 clinical trial for addressing muscle wasting in patients with obesity. The company aims to preserve muscle function and enhance functional outcomes for patients.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| 2016-11-09 18:00 |
BIOPHYTIS participera à la Jefferies Conference de Londres et à l’European Midc…
|
French | 597.1 KB | ||
| 2016-11-09 18:00 |
BIOPHYTIS to attend to Jefferies conference (London) and European Midcap event …
|
English | 592.2 KB | ||
| 2016-10-24 08:30 |
BIOPHYTIS chooses Patheon to produce the clinical batches of Macuneos, its AMD …
|
English | 522.8 KB | ||
| 2016-10-24 08:30 |
BIOPHYTIS choisit Patheon pour la fabrication des lots cliniques de Macuneos, c…
|
French | 533.0 KB | ||
| 2016-10-11 08:30 |
BIOPHYTIS met en place SARA-data, une plate-forme e-Santé pour le développement…
|
French | 548.6 KB | ||
| 2016-10-11 08:30 |
BIOPHYTIS to implement company’s SARA-data e-Health platform for clinical deve…
|
English | 537.2 KB | ||
| 2016-09-22 08:30 |
BIOPHYTIS lance la deuxième phase de l’étude de pharmacocinétique de Sarconeos …
|
French | 511.3 KB | ||
| 2016-09-22 08:30 |
BIOPHYTIS launches the second phase of Sarconeos pharmacokinetics study (SARA-P…
|
English | 506.9 KB | ||
| 2016-09-13 08:31 |
BIOPHYTIS ready to launch SARA-OBS trial
|
English | 131.4 KB | ||
| 2016-09-13 08:31 |
BIOPHYTIS prêt à lancer l’étude SARA-OBS
|
French | 137.1 KB | ||
| 2016-09-05 19:00 |
Présentation de BIOPHYTIS à la 18ème Conférence annuelle Rodman & Renshaw Globa…
|
French | 506.2 KB | ||
| 2016-09-05 19:00 |
BIOPHYTIS will present at the Rodman & Renshaw 18th Annual Global Investment Co…
|
English | 608.2 KB | ||
| 2016-08-26 09:00 |
Biophytis : Inclusion des premiers sujets dans l’étude de pharmacocinétique su…
|
French | 510.4 KB | ||
| 2016-08-26 09:00 |
BIOPHYTIS: enrollment of the first subjects in the pharmacokinetics study on Sa…
|
English | 502.2 KB | ||
| 2016-07-29 08:00 |
BIOPHYTIS obtient l’accord de bpifrance pour une aide à l’innovation de 1,…
|
French | 113.5 KB |
Automate Your Workflow. Get a real-time feed of all Biophytis S.A. filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for Biophytis S.A.
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for Biophytis S.A. via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| 2023-11-22 | N/A | Other | Buy | 8,443,190 | 79,365.99 EUR |
| 2020-12-16 | N/A | Other | Sell | 500,000 | 499,000.00 EUR |
| 2020-12-16 | N/A | Other | Other | 313,417 | N/A |
| 2020-04-30 | N/A | Other | Other | 2,955,701 | 177,342.06 EUR |
Peer Companies
